J&J guns for quick drug OK in lung cancer niche, taking the first step challenging AstraZeneca in EGFR
J&J has leapt straight from a Phase I trial to a BLA for amivantamab, a bispecific antibody designed to treat a subset of metastatic non-small cell lung cancer patients by targeting EGFR and MET simultaneously.
While the first epidermal growth factor receptor inhibitors were approved more than a decade ago, this is the first drug targeting EGFR exon 20 insertion mutations to ever be filed with the FDA, the company said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.